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To determine the efficacy and tolerability of SPI-77 (sterically stabilised liposomal cisplatin) at three dose levels in patients with
advanced non-small-cell lung cancer (NSCLC). Patients had Stage IIIB or IV NSCLC and were chemo-naı ¨ve, and Eastern Oncology
Cooperative Group 0–2. The first cohort received SPI-77 at 100mgm
 2, the second 200mgm
 2 and the final cohort 260mgm
 2.
Patients had also pharmacokinetics and analysis of leucocyte platinum (Pt)-DNA adducts performed. Twenty-six patients were
treated, with 22 patients being evaluable for response. Only one response occurred at the 200mgm
 2 dose level for an overall
response rate of 4.5% (7.1% at X200mgm
 2). No significant toxicity was noted including nephrotoxicity or ototoxicity aside from
two patients with Grade 3 nausea. No routine antiemetics or hydration was used. The pharmacokinetic profile of SPI-77 was typical
for a liposomally formulated drug, and the AUC appeared to be proportional to the dose of SPI-77. Plasma Pt levels and leucocyte
DNA adduct levels did not appear to rise with successive doses. SPI-77 demonstrates only modest activity in patients with NSCLC.
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One of the principal aims of anticancer drug development is to
improve efficacy and reduce toxicity through greater tumour
specificity. Liposomal formulations of drugs have long held
promise as a drug vehicle. Initial difficulties of a rapid clearance
of liposomes from the circulation by the macrophages of the
reticulo-endothelial system were resolved with the development of
sterically stabilised liposomes. Through the addition of methoxy-
polyethylene glycol moieties on the lipid bilayer surface, these
sterically stabilised (or STEALTH
s) liposomes demonstrated
prolonged circulation times.
Liposomes have several theoretical benefits that make them
attractive as vehicles for anticancer agents. Through encapsulation
of the cytotoxic agent, they reduce the potential for side effects
resultant from free circulating drug (Ranson et al, 1997). Another
theoretical advantage of liposomes is their preferential accumula-
tion in the tumour interstitium rather than the microenvironment
of healthy tissues. This phenomenon may be due to the passive
movement of liposomes through the walls of ‘leaky’ tumour
vasculature (Ogihara Umeda et al, 1996). This has ultimately
translated into the development of liposome-encapsulated cyto-
toxic agents with demonstrated activity (Ranson et al, 1997; Fossa
et al, 1998).
Cisplatin has been demonstrated to impact positively on
survival in advanced non-small-cell lung cancer (NSCLC) (1995),
but a downside is substantial systemic toxicity. Liposomal
encapsulation of cisplatin has the attraction of potentially reduced
toxicity, as well as the potential for tumour targeting. ALZA
Pharmaceuticals
s (Mountain View, CA, USA; formerly SEQUUS
Pharmaceuticals) developed a STEALTH
s (sterically stabilised)
liposomal formulation of cisplatin (SPI-77) that showed promising
results in preclinical models, with significantly greater tumour
growth delay than cisplatin. In subsequent phase I studies, the
dose was escalated to 320mgm
 2 with the dose-limiting toxicity
(DLT) of severe proximal myopathy (Meerum Terwogt et al, 2002).
In this study, chemo-naive patients with advanced NSCLC were
treated with SPI-77 at different dose levels, with the primary end
points of response and toxicity, and the secondary end points of
survival.
MATERIALS AND METHODS
Patient selection
Eligible patients were required to have histologically or cytologi-
cally documented Stage IIIB or IV NSCLC deemed not amenable to
therapy with curative intent. Patients were required to be chemo-
naive, have measurable disease, Eastern Oncology Cooperative
Group (ECOG) performance status of 0–2, 24h creatinine
clearance X50mlmin
 1, adequate bone marrow reserve
(HbX10.0gdl
 1, neutrophilsX1500mm
 3, plateletsX100000mm
 3)
and adequate hepatic function (serum bilirubin p34mmoll
 1,
transaminases p2 times ULN). Specific exclusion criteria included
clinically significant neuropathy or hearing loss.
All patients gave informed, written consent and the trial was
approved by the local research ethics committee and conducted in
accordance with good clinical practice obligations.
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The first cohort of patients received SPI-77 at a dose of 100mgm
 2
every 3 weeks. The second group received SPI-77 at 200mgm
 2
and the third group received 260mgm
 2. The initial dose level was
chosen as an acceptable standard dose of cisplatin, and the final
dose level was based on the maximum tolerated dose in the phase I
study. SPI77 was administered as an intravenous (i.v.) infusion
over 1h. No routine premedication or antiemesis was given. No
additional hydration or diuresis was given. Patients received up to
six cycles of treatment in the absence of unacceptable toxicity or
disease progression.
Assessment of response and toxicity
At baseline, patients were assessed with a physical examination
(including a meticulous neurological examination), an audiogram
and assessment of renal function with calculated or measured 24h
creatinine clearance, and a
51Cr-EDTA isotopic GFR scan. Serum
chemistry and electrolytes, liver function tests, lipid profile and full
blood count was tested.
At cycle completion, reassessment included measured 24h
creatinine clearance, serum chemistry, full blood count and
urinalysis. At treatment completion, patients were additionally
assessed with audiometry and isotopic GFR scan.
Disease status was assessed at the beginning of treatment and
after every other cycle, with either radiological examination (chest
radiograph, computer tomography scan) or physical examination.
Response was assessed according to standard World Health
Organisation (WHO) criteria. Toxicities were graded according
to National Cancer Institute (NCI) common toxicity criteria (CTC
version 2).
Statistical analysis
Patients who met all eligibility criteria and received X2 cycles
were included in response assessment. Fifteen patients were
planned to enter the study, with consideration to recruiting 10
extra patients if one or more responses occurred. The primary
study end points were response rate and toxicity, with the
secondary end points of overall survival and time to progression.
Time to progression was taken from date of first treatment to date
of progression. Survival was calculated from date of first treatment
to death.
Pharmacokinetic analysis
Pharmacokinetic sampling was performed predosing, at the end of
the 2h infusion, 1, 3, 5, 24, 48, 72, 96h postinfusion completion
and on days 8, 15 of cycle 1. During subsequent cycles, samples
were collected predosing, at infusion completion and at days 8, 15
and 22. At each blood sampling, 5ml of whole blood was drawn
into a heparinised tube. The blood was centrifuged for 10min at
41C. Plasma (800ml) was removed and added to 7.2ml of 0.1%
Triton X-100 containing 0.2% HNO3. The samples were divided
into eight 1.0ml aliquots and stored at  201C. The remaining
plasma was ultrafiltered using an Amicon Centrifree ultrafiltration
device by centrifugation at 1500g for approximately 30min using a
fixed angle rotor. The ultrafiltrate was stored at  201C.
Data analysis was performed using ABBOTTBASE
s pharmaco-
kinetic systems software.
Each patient’s data were analysed by nonlinear least squares
regression to determine the individual pharmacokinetic para-
meters. This utilises iterative nonlinear regression analysis to
determine a set of pharmacokinetic parameters that measures f,a
target objective function. Data from all patients was best fit by a 1-
compartment linear model.
AUC extrapolated to infinity (AUC 0–N) was calculated as the
sum of AUC (0–t) and Cpred/lz, where Cpred is the predicted
concentration at time t. The apparent terminal elimination rate
constant (lz) was derived from the log-linear disposition phase of
the concentration time curve using least squares regression
analysis, with visual inspection of the data to determine the
appropriate number of data points to include in the calculation of
lz. The apparent terminal elimination half-life (t1/2) was calculated
as ln 2/lz. The AUC calculations were derived from nonlinear least
curves and uniform time/concentration combinations. In eight
patients (30.7%) out of 26 patients, data from ultrafiltrates were
analysed for free platinum (Pt) and this was expressed as a
percentage of total Pt.
Peripheral blood mononuclear cell preparation
An additional 20ml of whole blood from study participants was
obtained for peripheral blood mononuclear cells.
Two 10ml blood samples were layered with a pipette onto an
equivalent volume of Ficoll
s (GE Healthcare, Uppsala, Sweden) in
universal tubes. The tubes were centrifuged at 400g for 30min at
18–201C. The formed lymphocyte layer was transferred by pipette
to another tube, and washed with PBS by centrifugation at 100g for
10min at 18–201C. A further wash took place before the cells were
stored at  801C.
DNA isolation
Tissue samples were thawed to room temperature in a micro-
centrifuge tube and 600ml of nuclei lysis buffer (Promega
s,
Southampton, UK) (12ml 0.5% EDTA:50ml of lysis buffer).
Proteinase K (Sigma, 17.5ml of a 20mgml
 1 solution in ddH2O)
was added and samples were incubated overnight at 551C with
gentle shaking.
After digestion, 200ml of protein precipitation solution (Pro-
mega) was added to the microcentrifuge tube and samples were
vortexed for 20s. Specimens were placed on ice for 5min and then
centrifuged at 15000r.p.m. for 5min at 41C.
Supernatant (700ml) from each tube was aspirated and added to
800ml of isopropanol in a separate tube. Samples were inverted
several times until a DNA mass formed. The specimens were
centrifuged at 15000r.p.m. for 2min at 41C. The supernatant was
discarded and the DNA pellet was washed with 600ml of 70%
ethanol. Specimens were again centrifuged at 15000r.p.m. for
2min at 41C. Once more, the supernatant was discarded and the
specimens were allowed to air dry for at least 15min. Samples were
subsequently rehydrated with 100ml of distilled H2O. Specimens
were incubated at 651C for 1h with regular mixing. All samples
were then sonicated to ensure homogeneity and stored at  201C
until analysed.
DNA quantification
Two 10ml aliquots of the 0, 5, 10, 15, 20, 25, 37.5 and 50mgml
 1
calf thymus DNA (Sigma) standards were placed in wells of a 96-
well microtitre plate.
An aliquot of the sample to be analysed was diluted with
appropriate volumes of Buffer I and vortex-mixed. Ten microlitres
of the diluted sample was placed in each of two wells on the
microtitre plate. Hundred microlitres of Hoechst dye solution
(9ml ddH2O:1ml TNE buffer:10ml Hoechst dye (Hoechst 23358
(Polyscience, Niles, Illinois, USA))) was added to each well.
Fluorescence was measured using an FL500 fluorescence microtitre
plate reader and DNA concentrations were extrapolated from the
standard curve. The DNA concentration of each sample was then
corrected for the original dilution. Duplicate values varied by no
more than 5%.
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Pt analysis was carried out by inductively coupled plasma mass
spectrometry (ICP-MS), using a standard Plasma-Quad II instru-
ment (VG Elemental, Winsford, UK), fitted with a standard
autosampler and concentric nebuliser, using a method based on
that developed by Christodoulou et al (1996). Solutions were
prepared in 0.1 M nitric acid (Aristar grade, Merck Scientific, West
Drayton, UK), and the assay was calibrated against Pt-containing
solutions prepared by serial dilution from a certified reference
standard. Measurements were made at the two highest abundance
isotopic mass numbers, 194 (32.9%) and 195 (33.8%). The
calibration was linear (typical CV o2%) over the analytical
working range (0.01–100.0mgdm
 3). The Pt-blank reading,
obtained from the 0.1 M nitric acid stock solution was subtracted
from sample measurements, and in most cases was below 1% of
the sample measurement. Procedural blanks were prepared
alongside samples to test for inadvertent problems of contamina-
tion, but none were detected.
Solutions were diluted gravimetrically in acid-rinsed polyethy-
lene bottles. Blood plasma was generally diluted 20-fold with 0.1 M
nitric acid, and for samples with high Pt levels, greater dilution
factors were employed as necessary to bring the Pt concentration
within the working range. DNA solutions were resuspended in
0.1 M nitric acid (10ml) before direct aspiration into the ICP-MS.
In all cases, uniformity of analytical response was established by
the method of additions. The estimated analytical precision was
o710%, except for the DNA samples where the very low Pt
concentrations resulted in a lower precision of measurement,
estimated at B20%.
RESULTS
Patient characteristics
Twenty-six patients entered the study at the Christie Hospital,
Manchester and Weston Park Hospital, Sheffield between March
1998 and June 1999. Patient characteristics are listed in Table 1. A
total of 57.7% of patients were male and the median age was 61.5
years (range 45–76 years). Out of 26 patients, 19 patients (73%)
had a performance status of 1, and nine patients (35%) had
evidence of metastatic disease.
Chemotherapy administration
The 26 patients received a total of 100 cycles with a median
number of 3.5 cycles. Nine patients received SPI-77 at 100mgm
 2
for a total of 31 cycles (median three cycles); 12 patients received
treatment at 200mgm
 2 for a total of 48 cycles (median four
cycles); and five patients received treatment at 260mgm
 2 for a
total of 21 cycles (median four cycles). Only one patient received a
dose delay (of 1 week), owing to a falsely low creatinine clearance
result. No patients received a dose reduction.
Response and survival
Patients who fully met the entry criteria and who received and
completed at least two cycles of therapy were evaluable for
response and survival according to the protocol. Four patients
were not assessable for tumour response. Two patients had Stage
IIIA disease, one patient did not have the required histological
confirmation, and one patient died of early progression, having
received only one cycle.
No objective responses occurred at the 100mgm
 2 dose level.
One patient achieved a partial response at the 200mgm
 2 dose
level. The duration of the response was 63 days. No additional
responses occurred in the 260mgm
 2 group. Two patients
experienced a minor response; one patient at 100mgm
 2 and
another at 200mgm
 2. The response rate was 0% (0 patient out of
eight evaluable patients) at 100mgm
 2 and 10% at 200mgm
 2
(one patient out of 10 evaluable patients). There were no further
responses at the 260mgm
 2 so the response rate was 7.1% at doses
of X200mg (one patient out of 14 evaluable patients).
Median time to progression was 12 weeks. Median overall
survival was 23 weeks (range: 3.6–90.4 weeks).
Seven patients (27%) received second-line cisplatin-based
combination chemotherapy. One response was seen, four patients
had stable disease, and two patients progressed through treatment.
Toxicity
SPI-77 was extremely well tolerated at the administered schedule.
No significant myelosuppression occurred with the maximum
toxicity being Grade 2 anaemia in 30% of patients. Three of the 26
patients required at least one blood transfusion (Table 2).
Nonhaematological toxicities were generally mild and subjective
tolerability was excellent (Table 3). Two patients suffered Grade 3
nausea and vomiting (7.7%). Subsequent nausea was well
controlled with the use of 5HT3 receptor antagonists. Otherwise,
prophylactic antiemetics were not used routinely.
Four patients developed a mild rash (three erythematous
maculopapular, one psoriaform). Four patients experienced itch
(one episode of Grade 3 itch).
All study patients lacked a history of clinically significant
deafness. All patients received baseline audiograms. Out of 26
patients, 15 patients (57.7%) had abnormal audiograms of which
10 patients (67%) out of 15 patients had age-related high frequency
loss bilaterally, and five patients (33%) out of 15 patients had
moderate-severe sensori-neural loss bilaterally. Sixteen patients
had follow-up audiograms although 13 of these were abnormal at
baseline. Only one patient out of 16 patients had a significant
change, with a 40 decibel (dB) hearing loss at 2000Hz in one ear,
having had moderate to severe high frequency loss at baseline.
Another patient was noted to a have a slight deterioration in acuity
at 4000–8000Hz, on a background of moderate high frequency
loss at baseline. The median cumulative dose of cisplatin received
by the 16 patients was 600mgm
 2.
Table 1 Patient’s characteristics (n¼26)
No. %
Total 26
Sex
Male 15 57.7
Female 11 42.3
Age (years)
Median 61.5
Range 45–76
Histology
Adeno 6 23
Squamous 14 54
Large 3 12
Other 3 12
Performance status (ECOG)
00 0
1 19 73.1
2 7 26.9
Disease stage
IIIA 2 7.7
IIIB 15 57.7
IV 9 34.6
ECOG¼Eastern Oncology Cooperative Group.
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nerves, testing pinprick sensation, proprioception, vibration and
deep tendon reflexes, at baseline and following each cycle. No
changes in clinical signs occurred in any patients over the course
of treatment.
Patients were assessed pretreatment and at the end of each cycle
with either a measured or calculated creatinine clearance. The
mean GFR by
51Cr-EDTA at baseline for the 26 patients was
80.6mlmin
 1 (median 90.23mlmin
 1, range 55–166mlmin
 1).
At the end of treatment, out of 26 patients, 17 patients (65.4%) also
had a follow-up
51Cr-EDTA isotopic GFR scan. The mean %
change in GFR following treatment was  2.16% (median þ1.3%,
range  27.4 to þ20%). The remainder of the group was assessed
with a measured or calculated creatinine clearance, with no
significant change seen from baseline.
Pharmacokinetics
One of the two treating centres participated in pharmacokinetic
analysis of SPI-77, with data being obtained from 17 patients. A
total of 710 samples from 355 time points were collected and
analysed from the 17 patients. Nine patients were evaluated at the
100mgm
 2 dose level, six patients at 200mgm
 2 and two patients
at 260mgm
 2.
The AUC of Pt (considered a reasonable surrogate for cisplatin/
SPI-77) over the first cycle (AUC1-22days) at the 100mgm
 2 dose
level was a mean of 823372369hmgml
 1 with a median value
of 9046hmgml
 1 and a range of 4333–11069hmgml
 1. The
mean AUC1-22days at the 200mgm
 2 dose level was
1982276187hmgml
 1 with a median value of 21236hmgml
 1
and a range of 10765–24139hmgml
 1. The mean and
median AUC1-22days at the 260mgm
 2 dose level was
2272974014hmgml
 1 and a range of 19891–25567hmgml
 1
(Table 3). No significant accumulation of SPI-77 was noted in
subsequent cycles and the AUCs for cycles 1 and 2 appeared
similar at all dose levels (Figure 1). The mean AUC1-22dayss
appeared to increase linearly with dose (r
2¼0.54).
Drug concentration declined in a mono-exponential way with a
mean t1/2 of 107.4725.29h (median 108h, range 62.3–168h)
(Figure 2). Plasma clearance of SPI-77 had a mean of 0.02181lh
 1
(median 0.0188lh
 1, range 0.0099–0.0416lh
 1) and was indepen-
dent of dose (Table 3). The apparent volume of distribution (Vd)
had a mean of 3.134l (median 3.24l, range 2.07–4.08l) that
approximates to plasma volume, and was independent of dose.
Eight patients (30.7%) were assessed for free (ultrafiltrated) Pt
levels. These were universally very low, with a mean value of
0.139% of the corresponding total Pt (median 0.048%, range
0.0015–1.1022%). In two patients who were assessed for ultra-
filtrated Pt levels over the first two cycles, the Cmax occurred at
days 3 and 4 with levels of 0.15–0.16mgml
 1.
Table 2 Toxicity (haematological and nonhaematological) (n¼26)
Toxicity No. %
Thrombocytopenia
Grade 1/2 — —
Grade 3/4 — —
Neutropenia
Grade 1/2 1 3.8
Grade 3/4 — —
Anaemia
Grade 1/2 21 81
Grade 3/4 — —
Nausea
Grade 1/2 10 38
Grade 3 2 7.7
Vomiting
Grade 1/2 5 19.2
Grade 3 2 7.7
Itch
Grade 1/2 3 11.5
Grade 3 1 3.8
Febrile reaction
Grade 1 2 7.7
Rash
Grade 1/2 4 15.3
Taste
Grade 1/2 3 11.5
Tinnitus
Grade 1/2 1 3.8
Table 3 Pharmacokinetic parameters of patients treated with 100–260mgm
 2 SPI-77 i.v. during days 1–22
AUC1–22 (hlgml
 1) Clearance (lh
 1) Vd (l) Half-life (h)
Dose SPI-77 (mgm
 2) Mean s.d. Mean s.d. Mean s.d. Mean s.d.
100 8233 2369 0.024 0.01 3.21 1.44 99.28 19.44
200 19822 6186 0.019 0.002 3.00 0.7 120.83 32.31
260 22729 4013 0.022 0.004 3.2 0.06 103.95 17.04
AUC¼area under the curve; i.v.¼intravenous; s.d.¼standard deviation; Vd¼volume of distribution.
Time (days)
0 20 40 60 80 100 120 140 160
P
l
a
s
m
a
 
p
l
a
t
i
n
u
m
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(

g
 
m
l
–
1
)
0
20
40
60
80
100
120
140 Actual concentration
Fitted concentration
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SPI-77 200mgm
 2 i.v. 3 weekly over six cycles.
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lymphocyte collection. Cisplatin-DNA adducts were measured over
the course of the first two cycles. At 100mgm
 2, the adduct levels
peaked at 1517186pgPtmg
 1 DNA on day 4 of cycle 1. A small
rise in cisplatin-DNA adduct formation was seen again following
the second cycle of SPI-77. The mean levels were lowest at day 1 of
the second cycle (18711pgPtmg
 1 DNA). There was no evidence
of accumulation of adducts over time as they returned to
pretreatment levels at the end of cycles 1 and 2 (Figure 3). There
was no evidence of increased adduct formation when the dose was
increased from 200 to 260mgm
 2.
DISCUSSION
The phase II study tested three different doses of SPI-77 to assess
activity and toxicity of SPI-77 over an extended number of cycles.
Cumulative toxicity is a common clinical problem with conven-
tional cisplatin and has also been a significant problem with
STEALTH
s liposomal doxorubicin (Ranson et al, 1997). A total of
100 cycles of SPI-77 at 100–260mgm
 2 were administered to the
26 patients with a median of 3.5 cycles per patient. The experience
at higher cumulative doses in the current trial was far greater than
the initial phase I study where 21 patients were treated for a total of
59 cycles, at dose levels ranging from 40 to 320mgm
 2,a ta
median number of two cycles per patient (Meerum Terwogt et al,
2002).
The objective overall response rate of 4.5% to SPI-77 was
disappointing, even for a single agent in NSCLC. No responses
were seen at 100mgm
 2. If only patients treated at X200mgm
 2
were included in response analysis, the response rate was 7.1%.
This compares with the activity of single-agent cisplatin in
advanced NSCLC of 6–32% in various studies (Thatcher, 1995).
The one patient who achieved an objective or partial response
progressed by cycle 5. Two other patients had minor responses to
SPI-77. The median overall survival of 23 weeks was relatively
short compared with the survival of patients treated with single-
agent cisplatin in other recent studies (Wozniak et al, 1998;
Sandler et al, 2000). Performance status plays an important role in
influencing the duration of longer survival with treatment of
advanced NSCLC (Thatcher et al, 1995). Given that the patients
had relatively good performance status (with PSp1 in 73.1%), the
disappointing survival in this phase II study would be consistent
with SPI-77 having low activity as a single agent in advanced
NSCLC.
In contrast to the well-known potential consequences of
conventional cisplatin such as nausea, myelosuppression, nephro-
toxicity and neurotoxicity, SPI-77 was extremely well tolerated in
all patients. Despite the extremely high Cmax and AUC plasma
levels of SPI-77, toxicities typical of conventional cisplatin were
not seen. This underscores the ability of STEALTH
s liposomes to
reduce drug toxicity. In this study, myelosuppression was not
clinically significant, with no instances of Grade 3/4 or thrombo-
cytopenia. Mild anaemia was common with 31% of patients having
Grade 2 anaemia although only three patients required a blood
transfusion.
Nonhaematological toxicity was also mild with SPI-77. Grade 3/4
nausea occurred in 7.7% of patients, with no other requirement in
the other patients for routine antiemetic treatment such as 5HT3
receptor antagonists. This is in contrast to the usual antiemetic
protocols required with conventional cisplatin therapy. In the
current study, there were instances of hypersensitivity reactions to
SPI-77 during the infusion in two patients. Four patients had
varying grades of itch, and four patients had a skin rash. None
of the patients developed the type or severity of rash that is
encountered with STEALTH
s liposomal doxorubicin therapy
(Ranson et al, 1997).
In the case of neurotoxicity, there was no evidence of clinically
significant peripheral neuropathy. Additionally, none of the
patients showed signs of a proximal myopathy, a feature that
was reported in two patients treated at 320mgm
 2 in the phase I
study of SPI-77 (Meerum Terwogt et al, 2002). Only one patient
exhibited a change in audiometry with a 20dB unilateral hearing
loss. Although this loss occurred at the typical frequency of normal
human speech, the patient concerned denied any tinnitus or
subjective change in hearing. In contrast, a study that examined
the ototoxicity of conventional cisplatin at doses of 50–
100mgm
 2 found that deterioration in audiometry post-therapy
was frequent (Schaefer et al, 1985) with higher frequency loss
(4000–8000Hz) common at cumulative doses of 200mg. The
authors concluded that cisplatin ototoxicity was dose-dependent.
Ototoxicity was not consistently seen with SPI-77 despite high
cumulative Pt doses (median 600mgm
 2, range 200–
1560mgm
 2), suggesting that cisplatin neurotoxicity was con-
siderably reduced with liposomal encapsulation
Nephrotoxicity was the DLT in the early studies of conventional
cisplatin (Finley et al, 1985). In a previous study of conventional
cisplatin, 15 patients who had received 100mgm
 2 every 3 weeks
for a median of three cycles had a fall in creatinine clearance from
112mlmin
 1 at baseline to 65mlmin
 1 at treatment completion.
Time (days)
01 0 2 0 3 0 4 0
P
l
a
s
m
a
 
p
l
a
t
i
n
u
m
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(

g
 
m
l
–
1
)
0
10
20
30
40
Figure 2 Population concentration over time curve for patients treated
with 100mgm
 2 SPI-77 during cycle 1.
Time (days)
04 0 30 20 10 50
P
t
–
D
N
A
 
a
d
d
u
c
t
s
 
(
p
g
 
P
t
 

g
 
D
N
A
–
1
)
0
100
200
300
400
Figure 3 Pt-DNA adducts in patients receiving 100mgm
 2 SPI-77 i.v. 3-
weekly.
Phase II study of SPI-77 in advanced NSCLC
SC White et al
826
British Journal of Cancer (2006) 95(7), 822–828 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sHowever, GFR did not change significantly during the course of
SPI-77 treatment. Additionally, aggressive hydration schedules are
routinely used to reduce the incidence of cisplatin-induced acute
renal dysfunction, whereas in this study, patients received no
additional hydration or forced diuresis.
The data from the trial reported here have demonstrated that the
toxicity profile of SPI-77 was markedly different from conventional
cisplatin at either standard doses (75–100mgm
 2) or experi-
mental high doses (4100mgm
 2). This reduced toxicity owing to
liposomal encapsulation has been noted with other liposome-
encapsulated cytotoxic agents such as Daunoxome
s or Caelyx/
Doxil
s (Ranson et al, 1997; Fossa et al, 1998).
In the case of doxorubicin and cisplatin, side effects such as
cardiomyopathy (doxorubicin) and nephrotoxicity (cisplatin) have
been partly attributed to high levels of peak free drug (Minow et al,
1977; Nagai et al, 1986). In a study by Nagai et al (1986), the
plasma Cmax of ultrafiltrated Pt was the most useful pharmaco-
kinetic marker for cisplatin nephrotoxicity. In our study, free
cisplatin levels were extremely low in plasma, with a mean value of
0.09mgml
 1. In the two patients who were assessed by determina-
tion of serial ultrafiltrated Pt levels, the peak Pt concentration of
0.15–0.16mgml
 1 was 60-fold lower than levels in patients
postbolus treatment with 100mgm
 2 of conventional cisplatin in
a previous study (Vermorken et al, 1982). In conclusion, the
improved toxicity profile of SPI-77 was likely to be due to stable
encapsulation of cisplatin by the liposomes, resulting in minimal
free Pt in plasma.
The pharmacokinetics of SPI-77 was assessed in 17 of 26
patients enrolled in the trial. The plasma AUCs of Pt (considered a
reasonable surrogate for cisplatin/SPI-77) levels were 100-fold
higher than have been reported for conventional cisplatin at
100mgm
 2 (Johnsson et al, 1996). Plasma clearance of SPI-77 was
lower, and t1/2 longer compared to conventional cisplatin. Vd in
SPI-77 was equivalent to plasma volume, in contrast to cisplatin
that has a larger Vd of 11–24l (Andersson et al, 1996; Johnsson
et al, 1996). Accordingly, the pharmacokinetic behaviour of SPI-77
follows the typical model of a STEALTH
s liposome-encapsulated
drug.
The levels of free Pt following SPI-77 were noted to be a minute
fraction (0.139%) of the total plasma Pt. It is unclear whether the
free cisplatin appears in the plasma as a result of release of drug
following degradation of the liposomes by the macrophage–
monocyte system or whether the drug becomes bioavailable in
plasma following breakdown of the liposomal membrane in the
circulation.
Pt-DNA adduct formation was assessed in 17 of the patients
with higher levels noted than previously seen in other studies
of cisplatin-treated patients. As lymphocyte cisplatin-DNA
adducts are presumed to arise from exposure in vivo to free
cisplatin, lower levels of adducts might have been expected as a
consequence of the extremely low plasma free Pt levels post-SPI-77
and this may be a result of carry-over of liposomal Pt during Ficoll
separation of lymphocytes and release during later processing.
Alternatively, it may be the result of enhanced exposure of
lymphocytes to SPI-77 liposomes entrapped in the reticulo-
endothelial system sinusoids.
SPI-77 is a novel formulation of cisplatin, encapsulated in
sterically stabilised liposomes. Its toxicity in humans is mild, with
almost no evidence of Grade 3/4 haematological or nonhaemato-
logical toxicity. No significant toxicity peculiar to SPI-77 was
noted, with only an occasional mild rash or infusion-related
hypersensitivity reaction. This is contrast to palmar-plantar
erythema that occurs with Caelyx/Doxil
s SPI-77 was easily dose-
escalated to 260mgm
 2 and total cumulative doses of up to
1560mgm
 2 were administered without reaching acute or
cumulative DLT.
Toxicity, mainly in the form of liver damage, hampered the
execution of tumour xenograft experiments testing SPI-77
(Colbert, 1999). Interestingly, such toxicity was neither demon-
strated in larger animals, nor in the present human studies. The
interspecies differences in the tolerability of SPI-77 probably
reflect differences in the metabolism of the acute lipid-loading
inherent with SPI-77. A single published study and unpublished
data from our group have demonstrated SPI-77 activity against a
variety of tumour xenograft models (Newman et al, 1999). Tumour
growth delay was significantly longer in tumour xenografts treated
with SPI-77 in comparison to conventional cisplatin.
The promising activity of SPI-77 in the animal xenograft studies
was not replicated in the clinical trial of patients with advanced
NSCLC. In the current phase II study, the response rate was a
modest 4.5%. Similarly, no objective tumour responses occurred in
the 24 patients in the phase I study (Meerum Terwogt et al, 2002),
and also in another phase II study in a similar population (Kim
et al, 2001). Three responses (out of 17 patients) were seen with a
combination of SPI-77 and vinorelbine in a phase I study (Vokes
et al, 2000). In patients with head and neck tumours, it has been
administered safely with radiation, but as a single agent was
disappointing with no responses (Harrington et al, 2001; Rosenthal
et al, 2002).
The response rate in this phase II study of SPI-77 appears
inferior to other known active single agents in NSCLC, including
conventional cisplatin, carboplatin and newer agents such as
gemcitabine (Thatcher et al, 1995). Despite the minimal toxicity of
the drug, SPI-77’s low activity in advanced NSCLC does not justify
further clinical studies in this disease setting.
As significant antitumour activity was demonstrated in the
xenograft experiments, the reason for low activity in human
studies may relate to host differences or to differences between
xenografts and de novo cancers in humans. Additionally, the
ability to metabolise liposomal drugs is limited in rodents, yet such
formulations are well tolerated by higher species including
humans. It is therefore possible that drug metabolism may be
relevant to the differences in efficacy of SPI-77 in animal
xenografts compared to advanced NSCLC.
An alternative hypothesis for the lack of clear correlation
between preclinical and clinical efficacy of SPI-77 may relate to the
differences in tumours. The size, location and vascularity of the
tumours differ between xenograft tumours in mice and human
tumours. Differences in the degree of vascularity and vessel
permeability may lead to altered rates of liposomal diffusion into
the tumour interstitium. It is worth noting that to date the most
sensitive and attractive disease setting for STEALTH
s liposomal
doxorubicin is the setting of Kaposi’s sarcoma where high vessel
density and permeability are features. One might therefore theorise
that SPI-77 may also be more active in settings where high
vascularity and permeability are present.
The demonstrated activity of SPI-77 in human tumour
xenografts does not completely exclude an inherent problem of
the formulation of the cisplatin. The markedly protracted plasma
kinetics may mean that free drug delivery to tumours takes place at
a slow rate, thereby allowing adducts to be more successfully
repaired. Certainly, the low levels of ultrafiltrated Pt are suggestive
of retention of cisplatin by the liposomes, and it may be that the
liposomal encapsulation is too retentive a vehicle to allow release
of free drug. In the phase I study, two patients were assessed for
tumour levels of Pt-DNA adducts and these were found to be low.
This again could reflect either poor tumour penetration by the
liposomes or inadequate release of free drug (Meerum Terwogt
et al, 2002).
Although SPI-77 did not demonstrate sufficient activity to merit
further study in advanced NSCLC, the trial demonstrated that large
doses of liposomal cisplatin can be administered safely and with
little toxicity. If an improved formulation of liposomal cisplatin
can enhance drug delivery to the site of the tumour, then an agent
with good activity and minimal toxicity might be developed
for clinical use. Effective tumour targeting may optimise the
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advanced NSCLC. Its application may also be extended to other
cancers that are responsive to cisplatin, such as ovarian, head and
neck and oesophageal cancer.
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